



NDA 202429/S-012

SUPPLEMENT APPROVAL

Hoffmann-La Roche, Incorporated
Attention: Agnes Blicq, Pharm.D.
Associate Program Director, PDR Program Management
Genentech, Incorporated
1 DNA Way, MS #241b
South San Francisco, CA 94080

Dear Dr. Blicq:

Please refer to your Supplemental New Drug Application (sNDA) received October 27, 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zelboraf (vemurafenib), tablet, 240 mg.

We also refer to our approval letter dated April 17, 2017, which contained the following error:

Section "2.4 Dose Modification for Strong CYP3A4 Inducers" which was added into the Full Prescribing information within the label was inadvertently omitted from the Full Prescribing Information: Contents*.

This replacement approval letter incorporates the correction of the error. The effective approval date will remain April 17, 2017, the date of the original approval letter.

This supplemental application provides for updates to the Dosage and Administration, Drug Interactions, and Clinical Pharmacology sections of the package insert based on data from a pharmacokinetic trial evaluating the effect of concomitant use of strong CYP3A4 inducers on the systemic exposure of vemurafenib to fulfill PMR 1803-5.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Norma Griffin, Lead Regulatory Health Project Manager, at (301) 796-4255.

Sincerely,

{See appended electronic signature page}

Jeffery Summers, M.D.
Deputy Director for Safety
Division of Oncology Products 2
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JEFFERY L SUMMERS
04/17/2017